Pfenex (NYSEAMERICAN:PFNX) Releases Earnings Results, Meets Estimates

Pfenex (NYSEAMERICAN:PFNX) released its quarterly earnings data on Thursday. The biotechnology company reported $0.09 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.09, Fidelity Earnings reports. The business had revenue of $15.25 million for the quarter, compared to the consensus estimate of $14.80 million.

PFNX stock traded up $0.51 during trading on Friday, hitting $10.68. 573,902 shares of the company’s stock traded hands, compared to its average volume of 209,372. Pfenex has a 52 week low of $3.13 and a 52 week high of $11.39.

In other Pfenex news, insider Patrick K. Lucy sold 6,000 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $10.01, for a total transaction of $60,060.00.

PFNX has been the subject of several research reports. JMP Securities increased their price objective on shares of Pfenex from $13.00 to $17.00 and gave the company an “outperform” rating in a research report on Wednesday, September 11th. Cantor Fitzgerald initiated coverage on shares of Pfenex in a research report on Thursday, October 24th. They set an “overweight” rating and a $20.00 price objective for the company. Zacks Investment Research lowered shares of Pfenex from a “buy” rating to a “hold” rating in a research report on Thursday, October 10th. Finally, William Blair reiterated a “buy” rating on shares of Pfenex in a research report on Friday, October 11th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Pfenex has a consensus rating of “Buy” and a consensus target price of $14.92.

Pfenex Company Profile

Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study.

Further Reading: Do investors pay a separate front-end load every time they buy additional shares?

Earnings History for Pfenex (NYSEAMERICAN:PFNX)

Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with's FREE daily email newsletter.